Form 4: Maze Therapeutics SVP Sells Shares After Option Exercise

Amy Bachrodt, SVP of Finance at Maze Therapeutics, exercised stock options and subsequently sold an equal number of shares totaling 15,000, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Amy Bachrodt, SVP of Finance at Maze Therapeutics, engaged in a series of transactions on December 29 and December 30, 2025.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on September 29, 2025.
• Bachrodt acquired a total of 15,000 shares of common stock by exercising stock options at a price of $10.42 per share.
• Concurrently, Bachrodt disposed of a total of 15,000 shares of common stock through sales.
• The sales occurred at weighted average prices ranging from $40.0814 to $41.1583 per share.
• Following these transactions, Bachrodt's direct beneficial ownership of common stock remained at 12,965 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there is a sale of shares, it is immediately preceded by an option exercise for the same number of shares, indicating a 'sell-to-cover' or 'cashless exercise' strategy, often for tax purposes or to realize gains from vested options. The execution under a 10b5-1 plan further reduces any negative implication, suggesting a pre-planned financial management strategy rather than a reaction to negative company news.

Positives

• The exercise of stock options indicates that the insider sees value in the company's stock, as they are converting options into shares.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests a systematic approach to managing equity rather than a reaction to immediate market conditions.

Negatives

• The sale of 15,000 shares by a senior executive could be interpreted as a reduction in direct exposure to the company's stock, although it was offset by option exercises.

Future Outlook

NA

Industry Context

This Form 4 filing details routine insider transactions for an executive at a biotechnology or pharmaceutical company (implied by 'Maze Therapeutics'). Such transactions, particularly when executed under a 10b5-1 plan, are common in the industry for executive compensation and personal financial planning, and do not typically reflect specific company or industry-wide strategic shifts.

Related Party Transactions

• The transactions involve an executive (Amy Bachrodt) of Maze Therapeutics, Inc. acquiring and disposing of company stock, which by definition constitutes a related party transaction (insider trading reportable under Section 16(a)).

Stakeholder Impact

• Shareholders: The transactions, being pre-planned under a 10b5-1 plan, are unlikely to signal new information about the company's prospects. The executive's beneficial ownership of common stock remained stable at 12,965 shares after the transactions, indicating continued alignment with shareholder interests through equity holdings.

Key Dates

Recommendation

The filing details routine insider transactions by a senior executive, specifically the exercise of stock options and the subsequent sale of an equivalent number of shares under a pre-arranged 10b5-1 trading plan. This type of transaction is typically for personal financial management, such as tax planning or diversification, and does not usually signal a change in the company's fundamental outlook or the executive's confidence. The beneficial ownership of the executive remains substantial. Therefore, based solely on this Form 4, there is no new information to warrant a change in investment thesis, leading to a 'hold' recommendation.

Keywords

Maze Therapeutics, MAZE, Insider Trading, Form 4, Stock Options, Share Sale, Amy Bachrodt, 10b5-1 Plan, Executive Compensation